O papel dos inibidores da enzima conversora de angiotensina e dos antagonistas dos receptores de angiotensina em pacientes com Covid-19: uma revisão narrativa
DOI:
https://doi.org/10.24220/2318-0897v30e2021a5035Palabras clave:
Anti-hipertensivos, Hipertensão, Infecções por coronavirus, Inibidores da enzima conversora de angiotensina, Sistema renina-angiotensina, Vírus da sars.Resumen
O objetivo deste trabalho é reunir e discutir os principais achados científicos, opiniões de especialistas e considerações de comunidades médicas a respeito da continuação do tratamento de pacientes hipertensos diagnosticados com Covid-19 em uso de anti-hipertensivos. Trata-se de uma revisão narrativa de literatura, restringida a publicações até abril de 2020, utilizando as bases de dados Medline e Embase e consulta a quatro sociedades científicas de Cardiologia. Um total de 93 publicações foram encontradas nas bases de dados consultadas, e, destas, nove publicações foram elegíveis para análise, sendo que seis publicações se mostraram favoráveis à continuação do tratamento com inibidores da enzima conversora de angiotensina e antagonistas dos receptores de angiotensina, o que foi ao encontro das recomendações das sociedades de Cardiologia; outras três publicações sugeriram que essas classes de anti-hipertensivos podem aumentar a gravidade da infecção. A continuação do tratamento com anti-hipertensivos durante a pandemia de coronavírus ou após o diagnóstico da infecção apresenta um paradoxo entre o potencial aumento da patogenicidade viral e a proteção pulmonar conferida pelo equilíbrio do sistema renina-angiotensina.
Descargas
Citas
World Health Organization. Coronavirus disease (COVID-19) Pandemic. Geneva: Organization; 2020 [cited 2020 Apr 13]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74. https://doi.org/10.1016/S0140-
(20)30251-8
Wan Y, Shang J, Graham R, Baric RS, Fang L. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94(7):1-9. https://doi.org/10.1128/JVI.00127-20
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-6. https://doi.org/10.1038/nature03712
Santos RAS, Simões AC, Maric C, Silva DMR, Machado RP, Buhr ID, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Nat Acad Sci. 2003;100(14):8258-63. https://doi.org/10.1073/pnas.1432869100
Liu Z, Bing X, Zhi XZ. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41(2):145-51. https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 2020;8(4):1. https://doi.org/10.1016/S2213-2600(20)30116-8
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):1-2. https://doi.org/10.1093/jtm/taaa041
Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19 clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. Br Med J. 2020;369:1-2.https://doi.org/10.1136/bmj.m1313
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537-40. https://doi.org/10.1002/ddr.21656
Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74. https://doi.org/10.1007/s11427-020-1643-8
Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-8. https://doi.org/10.1164/rccm.202002-0445OC
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):756-60. https://doi.org/10.1080/22221751.2020.1746200
Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 Pandemic. Hypertension. 2020;75:1382-5. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. Am Soc Microbiol. 2020;11(2):1-3. https://doi.org/10.1128/mBio.00398-20
Strabelli TMV, Uip DE. COVID-19 e o coração. São Paulo: Sociedade Brasileira de Cardiologia; 2020 [citado 14 abr 2020]. Disponível em: https://www.scielo.br/pdf/abc/2020nahead/0066-782X-abc-20200209.pdf
Canadian Cardiovascular Society. COVID-19 and concerns regarding use of ACEi/ARB/ARNi medications for heart failure or hypertension. Ottawa: Society; 2020 [cited 2020 Apr 14]. Available from: https://www.conferenceharvester.com/Uploads/Documents/9006/CCSCHFSstatementregardingCOVID.pdf
Oren O, Kopecky SL, Gluckman TJ, Gersh BJ, Blumenthal RS. Coronavirus disease 2019 (COVID-19): epidemiology, clinical spectrum and implications for the cardiovascular clinician. J Am Coll Cardiol. 2020 [cited 2020 Apr 14]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/04/06/11/08/covid-19-epidemiology-clinical-spectrumand-implications-for-the-cv-clinician
European Society of Cardiology. Position Statement of the ESC Council on hypertension on ACE- inhibitors and angiotensin receptor blockers. Sophia Antipolis: Society; 2020 [cited 2020 Apr 14]. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-CHT)/News/position-statement-of-the-esc-council-on-hypertensionon-
ace-inhibitors-and-ang
Santos L, Torriani MS, Barros E. Medicamentos na prática da farmácia clínica. Porto Alegre: Artmed; 2013.
Lombardi NF, Eduardo A, Mendes M, Lucchetta RC, Luiza M, Fávero D, et al. Análise das discrepâncias encontradas durante a conciliação medicamentosa na admissão de pacientes em unidades de cardiologia: um estudo descritivo. Rev Lat Am Enferm. 2016;24(2760):1-7. https://doi.org/10.1590/1518-8345.0820.2760
